Request Sample Form


Phone No.*:


Service Intersted In:

Download Complete Report

Your Name*:


Contact Number*:


Service Interested In* (required)

Your Requirment*:

First patient dosed in ADCT-402 Phase I trial for lymphoma

The drug is composed of a humanised monoclonal antibody that binds to human CD19, internalising into the cell where enzymes release the PBD-based warhead.

February 14th, 2019|News|

Platinum nanoparticles for selective treatment of liver cancer cells

Researchers recently demonstrated that platinum nanoparticles can be used to kill liver cancer cells with greater selectivity than existing cancer drugs.

February 14th, 2019|News|

Insulin Production By Reprogrammed Human Cell

The destruction of a single kind of insulin-producing cell in the pancreas can lead to diabetes — but a study suggests that other cells could be modified to take its place and help to control blood sugar levels.

February 13th, 2019|News|

How Biotech Is Changing The Way We Make Clothes

The fashion industry is seeing the beginnings of a biotechnological revolution where living beings are being used to make clothing, resulting in improved and more sustainable materials.

February 6th, 2019|News|

Kymriah gets NICE approval for DLBCL

The only CAR-T cell therapy available for NHS patients in England and Wales for two distinct blood cancers – will be available on the NHS in England and Wales to eligible adults who did not respond to two or more previous treatments with DLBCL, with funding from the Cancer Drugs Fund (CDF).

February 1st, 2019|News|

Attis, Novozymes Partner On Biotech For Ethanol Production

Under this newly announced relationship, Novozymes commits to supplying the enzymes required by Attis to convert its pulp into sugar at all of its planned biorefineries.

January 29th, 2019|News|

Japan’s approval of stem-cell treatment for spinal-cord injury concerns scientists

Japan has approved a stem-cell treatment for spinal-cord injuries. The event marks the first such therapy for this kind of injury to receive government approval for sale to patients.

January 24th, 2019|News|

Gene-editing tool CRISPR/Cas9 shown to limit impact of certain parasitic diseases

Researchers have successfully used CRISPR/Cas9 to limit the impact of schistosomiasis and liver fluke infection, which affects more than a quarter of a billion people in Southeast Asia, sub-Saharan Africa, and Latin America.

January 15th, 2019|News|

Janssen hands back rights to imetelstat

Janssen Biotech has decided to terminate a collaboration and license agreement with Geron Corp for experimental cancer drug imetelstat.

September 27th, 2018|News|